HomeAI · summaries
Storia in 3 fonti
ASCO26: In vivo oncology approaches continue to show promise
Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
pharmaceutical-technology.com
ASCO26: BMS and J&J debut shining multiple myeloma data - Pharmaceutical Technology
Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.
- ·
ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.
- ·
statnews.com
A turning point for pancreatic cancer patients
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
- ·
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.
- ·
endpoints.news
ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma
ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries
- ·
ASCO26: In vivo oncology approaches continue to show promise
Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.
- ·
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma - Pharmaceutical Technology
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.